Directions for improving adaptive management efficiency of manufacturing pharmaceutical companies

The aim of the article is to analyze the existing problems of adaptive management of manufacturing pharmaceutical companies and the development of methodological support for their management. Materials and methods. The research used methods of theoretical generalization, analysis and synthesis, synergetic approach and expert survey. 120 people were involved in the expert survey, divided into four groups: representatives of pharmaceutical manufacturing enterprises (30 people); representatives of pharmaceutical higher education institutions (30 people); pharmaceutical distributors representing wholesale companies (30 people); end users (30 people). Results. The article considers scientific and methodological approaches to improving adaptive management in the direction of forming competitive advantages of manufacturing pharmaceutical companies, the practical implementation of which requires business entities determination, flexibility and adequacy in the formation of modern management strategies and tactical planning and operational tasks of production, economic and commercial activities. There are external and internal factors influencing the formation of competitive advantages of the business entity. As the internal factors we include: organizational and legal form, and business entity organizational structure; the level of scientific and technical development of production; level of education and qualification of staff; business image of the enterprise; financial reputation of the enterprise. However, no less influence on the formation of competitive advantages of the management of manufacturing pharmaceutical companies have external factors, which, in contrast to internal, are not controlled by the entity: the state of the pharmaceutical market; technologies; workforce; scientific and technical development; etc. Conclusions. The directions of increasing the adaptive management efficiency are determined and it is concluded that the main criterion of efficiency is the quality of pharmaceutical products and the quality of management decisions in economic risks